• Hiroshi Matsumoto, Akiko Shiotani, Ryo Katsumata, Minoru Fujita, Rui Nakato, Takahisa Murao, Manabu Ishii, Tomoari Kamada, Ken Haruma, and David Y Graham.
• Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama Prefecture, 701-0192, Japan.
• Dig. Dis. Sci. 2016 Nov 1; 61 (11): 3215-3220.

BackgroundVonoprazan is a novel potassium-competitive acid blocker (P-CAB) recently approved for Helicobacter pylori eradication therapy in Japan.AimsTo compare PPI- and P-CAP-containing triple therapy and vonoprazan-based triple therapy.MethodsTwo hundred ninety-five initial subjects received a PPI-containing triple therapy; the next 125 subjects received vonoprazan-containing triple therapy. Two sequential groups received 7-day eradication regimens consisting of amoxicillin 750 mg, clarithromycin 200 mg both twice a day with standard dose PPI or vonoprazan (20 mg) each twice daily. H. pylori eradication was confirmed by a 13C-UBT. Clarithromycin susceptibility was evaluated by 23S rRNA PCR.ResultsPopulation cure rates with clarithromycin susceptible strains were 89.6 versus 100 % for PPI and vonoprazan therapies, respectively. Cure rates with resistant strains were 40.2 % with PPI therapy versus 76.1 % with vonoprazan triple therapy. There was no difference in side effects.ConclusionsAlthough 7-day P-CAB triple therapy was superior to 7-day PPI triple therapy, neither was highly effective, or can be recommended, in the presence of clarithromycin-resistant infections.

44 keywords...

hide…